Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 967 6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

TwongStocks Apr. 28 at 9:09 PM

$CTOR is non-compliant with NASDAQ's minimum bid price pule. Has until Oct 19, 2026 to regain compliance. https://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390026048629/ea0288020-8k_citius.htm Parent company $CTXR is also non-compliant with the bid price rule. CTXR has until Aug 10, 2026 to regain compliance.

1 · Reply

TwongStocks Apr. 23 at 3:14 PM

$CTXR Paid marketing campaign today. They usually have news whenever there is a scheduled campaign. No PR from $CTXR or $CTOR yet. https://bullseyealerts.com/ctxr-18/ "we received twenty two thousand five hundred dollars (cash) from Citius Pharmaceuticals (via Sica Media) for a one day marketing program starting on April 23, 2026" And on X https://x.com/bstocks7/status/2047306999981859030 "The Publisher has agreed to be paid $150 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about Citius Pharmaceuticals Inc (NASDAQ: CTXR) for a period beginning on 04/23/2026 and ending on 04/23/2026."

2 · Reply

SweStonk Apr. 22 at 4:46 PM

$CTOR will the mental barrier break? 🧐

0 · Reply

OfficialStocktwitsUser Apr. 22 at 3:46 PM

$CTOR RSI: 77.17, MACD: 0.0211 Vol: 0.13, MA20: 0.71, MA50: 0.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TwongStocks Apr. 21 at 2:38 PM

$CTOR $CTXR At the Centri Capital Conference, Leonard Mazur confirmed that data from the LYMPHIR Phase 1 trial at the University of Pittsburgh will be presented at the 2026 ASCO Annual Meeting. This trial is testing LYMPHIR combined with KEYTRUDA (pembrolizumab) in gynecologic cancers. TITLE: Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results. ABSTRACT#: 2564 POSTER SESSION: Developmental Therapeutics—Immunotherapy DATE: May 30 LINK: https://www.asco.org/abstracts-presentations/257907 The full, final abstract text will be available on May 21 at 05:00 PM EST.

0 · Reply

ArcanePulse Apr. 19 at 9:01 PM

$CTOR In February, the company announced its first reported revenue following the launch of LYMPHIR and signed an exclusive distribution agreement with Uniphar to expand access to the drug in the European Union.

0 · Reply

whathappenedtomyaccount Apr. 15 at 7:21 PM

$CTOR I'm a buyer after the reverse split

0 · Reply

jayhip Apr. 15 at 1:49 PM

$CTOR

0 · Reply

TwongStocks Apr. 14 at 8:45 PM

$CTXR $CTOR summary of today's Centri Capital conference https://event.summitcast.com/view/KrjsLipAGeqbsaZrYptLHv/bc9gfVGxV8NSQMaKCgJuGu LYMPHIR • Launch was done without a sales force in place. First salespeople came onboard this week. • Despite the lack of a sales force at launch, they were still able to move product. • Plan to eventually move some of those salespeople full time into Citius Oncology. Over the next year or so, as they generate more revenue. • Confirmed that the topline data from the Phase 1 trial at the University of Pittsburgh will be presented at the 2026 ASCO Annual Meeting. MINO-LOK "We're now engaged with the FDA on, on the latest clinical data that we generated. We're not sure which way that's gonna go, but hopefully at some point, we'll have resolution of this in the coming months." Last question of Q&A asked about financing - "We know that we are gonna require just some additional funds just to finish this, the hiring of our sales force. And after that, we should be moving off on our own as quickly as possible."

1 · Reply

TwongStocks Apr. 10 at 12:29 PM

$CTXR $CTOR Scheduled to present at the Centri Capital Conference April 14, 2026 3:45 pm EDT https://event.summitcast.com/view/KrjsLipAGeqbsaZrYptLHv/bc9gfVGxV8NSQMaKCgJuGu

0 · Reply

Market Cap	77.43M
Revenue (ttm)	0.00
Net Income (ttm)	-24.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.26

Volume	41,400
Avg Vol	278,186
Day's Range	N/A - N/A
Shares Out	88.28M
Stochastic %K	60%
Beta	3.42
Analysts	Strong Sell
Price Target	$6.00